BioRestorative Therapies

BioRestorative Therapies

Biotechnology
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

$2.4M

Market Cap • 10/9/2026

1997

(29 years)

Founded

1997

(29 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0

P/S

6,8

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

137,5

EPS

—

Market Cap

Market Cap

2,4M

EV

-1,2M

EV/Revenue

-3,2

EV/EBITDA

0,1

EV/EBIT

0,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-288,1%

Total Yield

-288,1%

Payout

0%

Profitability

Gross Margin

92,1%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

2619,4%

Capex/Revenue

22,3%

Capex/D&A

37,8%

Capex/OCF

-0,7%

SBC/OCF

—

% PPE

7,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

39%

CAGR Op. Income 5Y

-3,1%

CAGR Net Income 5Y

-15,8%

CAGR EPS 5Y

-50,5%

CAGR OCF 5Y

38,4%

Leverage

N.D./EBITDA

0,3

Debt/Equity

0%

Current Ratio

2,4

Quick Ratio

2,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium